Literature DB >> 31984804

NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.

Naim Alkhouri1.   

Abstract

Keywords:  NAFLD; biomarkers; elafibranor; firsocostat; hepatocellular carcinoma; liver fibrosis; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obeticholic acid; pioglitazone

Mesh：

Substances：

Year:  2020        PMID： 31984804     DOI： 10.1080/13543784.2020.1721169

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  4 in total

1.  Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.

Authors:  Romina Lomonaco; Eddison Godinez Leiva; Fernando Bril; Sulav Shrestha; Lydia Mansour; Jeff Budd; Jessica Portillo Romero; Siegfried Schmidt; Ku-Lang Chang; George Samraj; John Malaty; Katherine Huber; Pierre Bedossa; Srilaxmi Kalavalapalli; Jonathan Marte; Diana Barb; Danielle Poulton; Nada Fanous; Kenneth Cusi
Journal:  Diabetes Care       Date:  2020-12-21       Impact factor: 19.112

2.  Effect of Bombyx mori on the Liver Protection of Non-Alcoholic Fatty Liver Disease Based on In Vitro and In Vivo Models.

Authors:  Miey Park; Chaewon Kang; Hae-Jeung Lee
Journal:  Curr Issues Mol Biol       Date:  2021-04-28       Impact factor: 2.976

3.  Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.

Authors:  Yi Zhou; Junyan Tao; Diego F Calvisi; Xin Chen
Journal:  Semin Liver Dis       Date:  2021-07-26       Impact factor: 6.115

Review 4.  Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!

Authors:  Ioannis A Ziogas; Konstantinos Zapsalis; Dimitrios Giannis; Georgios Tsoulfas
Journal:  World J Hepatol       Date:  2020-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.